Overview

Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Status:
Completed

Trial end date:
2011-05-01

Target enrollment:

Participant gender:

Summary

This clinical trial will study the use of ridaforolimus in metastatic breast cancer subjects whose tumors have shown a resistance to trastuzumab (herceptin). The goal of this study is to find out if subjects treated with ridaforolimus in combination with trastuzumab have a positive response to the treatment, and if treatment with ridaforolimus in combination with trastuzumab prolongs survival.

Phase:

Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Sirolimus
Trastuzumab